NDAORALTABLET
Approved
Jan 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
EDECRIN (ethacrynic acid) by Bausch + Lomb. Approved for loop diuretic [epc]. First approved in 1967.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EDECRIN (ethacrynic acid) is a loop diuretic approved in 1967 that works by inhibiting sodium and chloride reabsorption in the ascending loop of Henle, promoting water excretion. It is indicated for the management of edema associated with congestive heart failure, hepatic cirrhosis, and renal disease, as well as hypertension.
$0.517MPart D
LOE ApproachingMinimal commercial activity with only $517K in annual Part D spending and 229 claims signals a legacy product with limited team investment and consolidation pressure.
Mechanism of Action
Pharmacologic Class:
Loop Diuretic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EDECRIN offers minimal career advancement opportunity given its legacy status, minimal market spend ($517K annually), zero linked job openings, and approaching loss of exclusivity. Working on this product typically involves maintenance-level responsibilities in a small, potentially consolidating team.
Brand ManagerField Sales Representative
Worked on EDECRIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.